Spinal Muscular Atrophy Market Report 2026

The spinal muscular atrophy market size has grown rapidly in recent years. It will grow from $4 billion in 2025 to $4.53 billion in 2026 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to approval of breakthrough sma therapies, increased genetic testing, advocacy group awareness, clinical trial investments, rare disease funding.

The spinal muscular atrophy market size is expected to see rapid growth in the next few years. It will grow to $7.34 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to next-generation gene therapies, global screening adoption, expanded treatment access, improved survival outcomes, pipeline drug development. Major trends in the forecast period include early genetic diagnosis, expansion of disease-modifying therapies, newborn screening programs, personalized treatment protocols, long-term disease management.

The rising prevalence of rare genetic diseases is expected to drive the growth of the spinal muscular atrophy market in the coming years. Rare genetic diseases are disorders caused by mutations in genes that affect a small segment of the population, often resulting in severe and chronic health conditions. The increase in these diseases can be attributed to improved diagnostic technologies, greater awareness, and better access to genetic testing, leading to more cases being identified and reported. Spinal muscular atrophy (SMA) is a rare genetic disorder that underscores the challenges and opportunities in understanding inherited conditions and highlights the importance of advancing research in this area. For instance, in July 2023, according to the Office for National Statistics, a UK-based government department, genetic testing of SMN1 has enabled precise epidemiological studies, showing that SMA occurs in 1 of 10,000 to 20,000 live births, with more than 95% of affected patients being homozygous for SMN1 deletion. Therefore, the rising prevalence of rare genetic diseases is fueling the growth of the spinal muscular atrophy market.

Key companies in the spinal muscular atrophy market are developing innovative products, such as dry syrup formulations, to improve medication adherence and ease of administration for pediatric patients and others with swallowing difficulties. Dry syrup is a powdered medication that is reconstituted with water before use, commonly prescribed for children or patients unable to swallow tablets or capsules. For example, in September 2024, Chugai Pharmaceutical Co., Ltd., a Japan-based company, received regulatory approval from Japan's Ministry of Health, Labour and Welfare to expand the indication of its drug Evrysdi (risdiplam) for pre-symptomatic SMA, including dosing for infants under two months old. This approval allows treatment to begin before symptoms appear, potentially enhancing therapeutic outcomes. Data from the RAINBOWFISH study showed that treated infants achieved developmental milestones, such as unsupported sitting and improved motor skills, by 12 months, highlighting the potential of early intervention to transform disease progression.

In January 2024, Voyager Therapeutics, Inc., a US-based biotechnology company, partnered with Novartis AG to advance gene therapies for Huntington’s disease and spinal muscular atrophy. The collaboration leverages Voyager’s proprietary TRACER capsids and cutting-edge technology. Novartis AG, based in Switzerland, develops pharmaceuticals, eye care products, and generic medicines.

Major companies operating in the spinal muscular atrophy market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Novartis AG, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Genentech Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., RegenXBio Inc., Cytokinetics Inc., AveXis Inc., Scholar Rock Inc., Genethon, CANbridge Pharmaceuticals Inc., NMD Pharma A/S, Hanugen Therapeutics Inc., Beijing Jinlan Gene Technology Co. Ltd, Sarepta Therapeutics, Amicus Therapeutics, Audentes Therapeutics, Solid Biosciences.

North America was the largest region in the spinal muscular atrophy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the spinal muscular atrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased costs in the spinal muscular atrophy market by raising prices for imported gene therapies, biologics, active pharmaceutical ingredients, and specialty drug formulations. Hospital pharmacies and specialty pharmacies in Asia-Pacific and Europe are most affected due to global pharmaceutical supply dependencies. These higher costs can restrict patient access to advanced SMA treatments. At the same time, tariffs are encouraging domestic biopharmaceutical production and biosimilar development, improving long-term treatment accessibility.

The spinal muscular atrophy market research report is one of a series of new reports that provides spinal muscular atrophy market statistics, including spinal muscular atrophy industry global market size, regional shares, competitors with a spinal muscular atrophy market share, detailed spinal muscular atrophy market segments, market trends and opportunities, and any further data you may need to thrive in the spinal muscular atrophy industry. This spinal muscular atrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder marked by the progressive loss of motor neurons in the spinal cord, resulting in muscle weakness and atrophy. It is caused by mutations in the SMN1 gene, which lead to insufficient production of survival motor neuron (SMN) protein. SMA primarily affects voluntary muscle movements, including those required for walking, swallowing, and breathing.

The main types of spinal muscular atrophy are type 1 (severe), type 2 (intermediate), type 3 (mild), and type 4 (adult). Type 1 SMA, also called severe SMA, is the most critical form, characterized by profound muscle weakness and the inability to sit or move independently, often resulting in death before the age of 2 without treatment. SMA affects various age groups, including pediatric and adult patients. Treatment options include drug therapy and gene therapy, and these are utilized by end users such as hospital pharmacies, online pharmacies, and retail pharmacies.

The spinal muscular atrophy market consists of revenues earned by entities by providing services such as gene delivery services, diagnostic services, and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The spinal muscular atrophy market also includes sales of therapy products, diagnostic kits, medical devices, and nutritional products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.